Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , SHANGHAI, Nov. 30 /PRNewswire-Asia/...aceutical, biotechnology, and medical-device resea...tions in China and the United States,announced th... Fast 50 China,2009 list for the fifth consecutive...companies in China,s technology, media, and teleco...
(Date:11/30/2009)... , AMSTERDAM, Nove...rld,s,leading publisher of scientific, medical and...a major re-launch of Embase, its comprehensive bio...ed records from more than 7,000,active, peer revie...key role in the advancement of new biomedical,and ...
(Date:11/28/2009)... The Vanuatu National Advisory ...cond National Communication (SNC) Project in colla...and CLIMsystems Ltd. of New Zealand have generated...ults that will form the background for the country...work Convention on Climate Change (UNFCCC). , ...
(Date:11/27/2009)... , PARIS, November 27 /PRNewswire-FirstCall...al to market Oralair(R) in both adults and childre... the first country where,Oralair(R) has been marke...alair(R) is now registered in Austria, Belgium, Bu...e, Germany, Greece, Hungary, Ireland, Italy,Latvi...
Breaking Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3
... ExonHit Therapeutics, a,drug and diagnostic disco...st blood-based Alzheimer,s disease test. The compa...ide it as a service in its GLP (Good,Laboratory Pr...cal industry,as early as 2009. This initial ExonH...lzheimer,s disease from a simple blood sample. Fur...
...Are Among The Organizations Advocating Use of Hand...and Protection, NORCROSS, Ga., Nov. 8 Headlines ...ureus) deadlier than AIDS, and the media continue,...the most extreme cases,student deaths due to this ...washing is advocated as one of the best means of p...
... Nov. 8 Ortho Biotech,Products, L.P. today modifi... alfa), following guidance from the U.S. Food and ...ll drugs within the,erythropoiesis-stimulating age...e based on previously reported data,and include re...s Advisory,Committee meeting, and the September 11...
Other Biology Technology:ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 2ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 3ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 4Soap and Water May not be Enough to Fight MRSA Superbug 2Soap and Water May not be Enough to Fight MRSA Superbug 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings 5
(Date:11/30/2009)...ajor obstacle to HIV research is the virus,s exqui...at scientists, traditional tools, like the humble ...ow, a team of researchers writing in BioMed Centra...ingenious assault on this problem by creating a mo... being infected with HIV. , George Kassiotis, fr...
(Date:11/30/2009)... , VILNIUS, Lithuania, Nov. 30 /PRNewsw...gy.com ), a provider of high-precision biometric i...pgrades in the company,s core product line: VeriL... recognition and MegaMatcher 3.1 SDK for large-s...ntification systems (AFIS). Expanded capabilities ...
(Date:11/26/2009)...zed for their impressive antlers, red deer have be...But a deer,s antlers are much more than decorative...r when duelling. John Currey, from The University ...properties of bone for over half a century and has... antler through a long-standing collaboration with...
Breaking Biology News(10 mins):A reductionist approach to HIV research 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Tough yet stiff deer antler is materials scientist's dream 2General anesthetics lead to learning disabilities in animal models 59954 1General anesthetics lead to learning disabilities in animal models 59954 2General anesthetics lead to learning disabilities in animal models 59954 3Extra care for outwardly healthy workers costs companies millions annually 59951 1Extra care for outwardly healthy workers costs companies millions annually 59951 2Nanowire biocompatibility in the brain 3A So far so good 10481 1Nanowire biocompatibility in the brain 3A So far so good 10481 2
...Lotions and potions that promise to remove wrinkle... shelves, but do these treatments really work? , V...have identified new molecular indicators -- or "bi...ed to evaluate anti-aging therapies. Their finding...l of Investigative Dermatology. , "There,s a lot ...
...Attaching a recently discovered cytokine to neural...at Cedars-Sinai Medical Center,s Maxine Dunitz Neu...k and kill malignant brain tumor cells and provide...lts of an animal study are published in the March ...ers are now applying to regulatory agencies to tra...
...A new study on identifying which patients were lik... liver transplant (LDLT) found that measuring how ...r shortly after surgery was an accurate indicator ...tor of the outcome of the procedure. The study use... making it particularly useful in treating transpl...
Other Biology News:Biomarkers may hone anti-aging therapies 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 3Predicting successful outcomes in living-donor liver transplants 2Predicting successful outcomes in living-donor liver transplants 3
...ot automates LC micro-fractionation, spotting and ...tem, LC eluent can be accurately and continuously ... allows for automatic preparation of target plates...nction with Shimadzus Two-Dimensional Micro LC Sys...
...-Jun NH2-terminal kinase) signal transduction casc... in mammals. JNK pathway activation occurs in resp...he nuclear accumulation of JNK itself, and is impl...ion, oncogenic transformation, morphogenesis, and ...
HP GenomeWide siRNA from QIAGEN
...Screen cDNA Library Panels were designed for full-... PCRs to identify the desired cDNA clone. The firs...late," where each well contains plasmid DNA from 5...) by gel electrophoresis of the reaction products,...
Biology Products: